1279 related articles for article (PubMed ID: 24018362)
1. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
2. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
4. Carbon nanotubes for delivery of small molecule drugs.
Wong BS; Yoong SL; Jagusiak A; Panczyk T; Ho HK; Ang WH; Pastorin G
Adv Drug Deliv Rev; 2013 Dec; 65(15):1964-2015. PubMed ID: 23954402
[TBL] [Abstract][Full Text] [Related]
5. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
Gan CW; Feng SS
Biomaterials; 2010 Oct; 31(30):7748-57. PubMed ID: 20673685
[TBL] [Abstract][Full Text] [Related]
6. Clinical translation of immunoliposomes for cancer therapy: recent perspectives.
Wang D; Sun Y; Liu Y; Meng F; Lee RJ
Expert Opin Drug Deliv; 2018 Sep; 15(9):893-903. PubMed ID: 30169978
[TBL] [Abstract][Full Text] [Related]
7. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
8. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.
Cruz LJ; Tacken PJ; Fokkink R; Figdor CG
Biomaterials; 2011 Oct; 32(28):6791-803. PubMed ID: 21724247
[TBL] [Abstract][Full Text] [Related]
9. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Hafner AM; Corthésy B; Merkle HP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
[TBL] [Abstract][Full Text] [Related]
10. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
11. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
Zhong Y; Meng F; Deng C; Zhong Z
Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
[TBL] [Abstract][Full Text] [Related]
12. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
13. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.
Heidel JD; Yu Z; Liu JY; Rele SM; Liang Y; Zeidan RK; Kornbrust DJ; Davis ME
Proc Natl Acad Sci U S A; 2007 Apr; 104(14):5715-21. PubMed ID: 17379663
[TBL] [Abstract][Full Text] [Related]
14. Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy.
Vijayakumar MR; Muthu MS; Singh S
Expert Opin Drug Deliv; 2013 Apr; 10(4):529-43. PubMed ID: 23316695
[TBL] [Abstract][Full Text] [Related]
15. Liposomal nanomedicines in the treatment of prostate cancer.
Kroon J; Metselaar JM; Storm G; van der Pluijm G
Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
[TBL] [Abstract][Full Text] [Related]
16. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT.
Tang J; Zhang L; Liu Y; Zhang Q; Qin Y; Yin Y; Yuan W; Yang Y; Xie Y; Zhang Z; He Q
Int J Pharm; 2013 Sep; 454(1):31-40. PubMed ID: 23850793
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting toxicity and efficacy of polymeric nanomedicines.
Igarashi E
Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
[TBL] [Abstract][Full Text] [Related]
18. Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.
Meher N; Ashley GW; Bobba KN; Wadhwa A; Bidkar AP; Dasari C; Mu C; Sankaranarayanan RA; Serrano JAC; Raveendran A; Bulkley DP; Aggarwal R; Greenland NY; Oskowitz A; Wilson DM; Seo Y; Santi DV; VanBrocklin HF; Flavell RR
Adv Healthc Mater; 2024 May; ():e2304618. PubMed ID: 38700450
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.
Eljack S; David S; Faggad A; Chourpa I; Allard-Vannier E
Int J Pharm X; 2022 Dec; 4():100126. PubMed ID: 36147518
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
